Table 1 Demographics
Slow infusion (n = 33) | Rapid infusion (n = 31) | |
|---|---|---|
Gender (female) | 25 (76) | 16 (52) |
Age, years | 69 (65–74) | 68 (55–74) |
BMI, kg/m2 | 25 (23–30) | 25 (23–27) |
ASA class 1 | 0 | 2 (6) |
ASA class 2 | 22 (65) | 21 (68) |
ASA class 3 | 11 (33) | 8 (26) |
Inclusion criteria | ||
PLR | 23 (70) | 20 (65) |
ScvO2 | 10 (29) | 9 (29) |
Lactate | 21 (62) | 20 (65) |
Urine production | 13 (38) | 13 (42) |
Systolic blood pressure | 9 (27) | 8 (26) |
Operation time, min | 368 (289–479) | 418 (365–467) |
Intraoperative bleeding, ml | 600 (300–1000) | 500 (300–1000) |
Epidural analgesia | 29 (88) | 30 (97) |
Intraoperative fluids | ||
Crystalloids, ml | 4250 (4000–5250) | 4250 (3500–5250) |
Colloids, ml | 500 (500–1000) | 700 (250–1000) |
Pre-treatment hemodynamics | ||
HR, beats/min | 84 (74–93) | 88 (71–97) |
Systolic blood pressure, mmHg | 114 (96–125) | 112 (99–129) |
MAP, mmHg | 77 (68–90) | 77 (68–88) |
CVP, cmH2O | 3 (0–6) | 3 (−1–8) |
Urine production, ml/kg/h | 0.8 (0.4–2.2) | 0.8 (0.5–1.0) |
Pre-treatment laboratory data | ||
Albumin, g/l | 31 (28–34) | 33 (31–35) |
Lactate, mmol/l | 2.2 (1.7–3.1) | 2.7 (1.5–3.2) |
ScvO2, % | 73 (67–76) | 73 (68–78) |
Hct (%) | 36 (34–38) | 35 (32–39) |
Glycocalyx components and hormones | ||
Hyaloronan, ng/ml | 153 (125–200) | 174 (132–208) |
Syndekan-1, ng/ml | 56 (32–96) | 91 (54–190) |
Glypican-4, ng/ml | 13 (10–17) | 13 (10–21) |
Copeptin, pmol/l | 138 (75–244) | 113 (71–207) |
MR-proANP, pmol/l | 85 (61–106) | 94 (71–139) |
Renin, mU/l | 51 (23–144) | 40 (19–131) |
Norepinephrine at the time of inclusion | 3 (9) | 1 (3) |